GSK Subsidiary Earns Greenlight for HIV Treatment

GlaxoSmithKline subsidiary ViiV Healthcare has earned EU marketing authorization for Dovato (dolutegravir/lamivudine), a two-drug regimen for treating HIV-1 infection.

The once-daily drug is cleared for treating HIV-1 infection in adults and adolescents over 12 years old that weigh at least 88 pounds and are not thought to have resistance to lamivudine.

Dovato’s European authorization means that HIV patients “can, for the first time, start treatment on a once-daily, single-pill, two-drug regimen with the knowledge that efficacy is non-inferior to a three-drug regimen whilst containing fewer antiretrovirals,” said ViiV Healthcare CEO Deborah Waterhouse.